Status:
COMPLETED
CD Patients Immune Status Evaluation
Lead Sponsor:
First Affiliated Hospital of Zhejiang University
Conditions:
Severe Crohn's Diease
Eligibility:
All Genders
18-80 years
Brief Summary
Using single cell sequencing method to evaluate and compare the immune status of patients with severe CD.
Eligibility Criteria
Inclusion
- 1, Patients with severe CD（CDAI\>16,SES-CD\>19） 2, Patients have no previous any drug therapy targeting CD or just received treatment of 5-ASA -
Exclusion
- 1, patients have previous treatment of prednisone, immunosuppressive agents such as azathioprine and biologic agents such as infliximab 2, patients were diagnozed as mild-moderate CD 3, patients have other immune disordered diseases such as SLE, PBC, AIH, PSC, sjogren syndrome, ulcerative colitis, and so on.
- \-
Key Trial Info
Start Date :
October 21 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04135482
Start Date
October 21 2019
End Date
July 31 2020
Last Update
February 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital, School of Medicine, Zhejiang University
Hanzhou, Zhejiang, China, 310003